Uncategorized
Phase 3 clinical trial enrollment begins for ocular allergy drug
Enrollment is underway for a second phase 3 clinical trial of Dextenza sustained release dexamethasone for treatment of allergic conjunctivitis, according to a press release from Ocular Therapeutix.The prospective, randomized, double-masked, vehicle controlled, multicenter trial will evaluate safety and efficacy of the 0.4 mg bioresorbable intracanalicular depot in patients with chronic symptoms of allergic conjunctivitis.